GlassScriptPhysician profile
Usman Choudhry
NPI 1497045504
$3,497.59
in general payments reported to CMS, 2019-2025
20 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,993 · 2020: $37.64 · 2021: $38.83 · 2022: $232 · 2023: $979 · 2024: $89.12 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,208.73 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Triclip, Mitraclip |
| Actelion Pharmaceuticals US, INC. | $249.45 | 2022-2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.01 | 2021-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $126.03 | 2022-2025 | Onpattro |
| Pfizer INC. | $106.75 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $97.59 | 2021-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $86.37 | 2022-2023 | Verquvo |
| United Therapeutics Corporation | $81.82 | 2022-2023 | Tyvaso, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.21 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $55.39 | 2022-2023 | |
| Amgen INC. | $45.01 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $31.68 | 2023 | |
| Baxter Healthcare | $23.22 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Daxor Corporation | $20.88 | 2023 | Bva-100 |
| Chiesi USA, INC. | $17.71 | 2025 | Cleviprex, Kengreal |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $16.38 | 2023 | Optimizer |
| Genzyme Corporation | $15.31 | 2023 | |
| Novo Nordisk INC | $15.00 | 2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $14.25 | 2023 | |
| Akcea Therapeutics, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Choudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.